NewEdge Advisors’s Lantern Pharma LTRN Stock Holding History

NewEdge Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Sell	27,049 -350	-1%	-$1.03K	﹤0.01%	2917
2026 Q1	$37.5K	Sell	27,399 -10,670	-28%	-$29.8K	﹤0.01%	3012
2025 Q4	$115K	Sell	38,069 -9,210	-19%	-$34.3K	﹤0.01%	2727
2025 Q3	$206K	Sell	47,279 -9,228	-16%	-$38.5K	﹤0.01%	2400
2025 Q2	$179K	Sell	56,507 -3,417	-6%	-$11.5K	﹤0.01%	2253
2025 Q1	$212K	Sell	59,924 -8,435	-12%	-$35K	﹤0.01%	2067
2024 Q4	$218K	Sell	68,359 -68,979	-50%	-$236K	﹤0.01%	2050
2024 Q3	$504K	Sell	137,338 -19,786	-13%	-$81.5K	﹤0.01%	1480
2024 Q2	$734K	Sell	157,124 -3,408	-2%	-$20.5K	0.01%	1209
2024 Q1	$1.41M	Sell	160,532 -5,440	-3%	-$29.1K	0.01%	831
2023 Q4	$710K	Sell	165,972 -4,059	-2%	-$14.3K	0.01%	1109
2023 Q3	$580K	Sell	170,031 -1,434	-0.8%	-$6.51K	0.01%	1106
2023 Q2	$967K	Sell	171,465 -650	-0.4%	-$3.36K	0.01%	886
2023 Q1	$831K	Sell	172,115 -723	-0.4%	-$3.8K	0.01%	866
2022 Q4	$1.04K	Buy	172,838 +1,819	+1%	+$9.11K	﹤0.01%	3025
2022 Q3	$817K	Buy	171,019 +1,047	+0.6%	+$5.63K	0.01%	732
2022 Q2	$971K	Buy	169,972 +201	+0.1%	+$1.2K	0.02%	677
2022 Q1	$1.21M	Buy	169,771 +2,665	+2%	+$17.8K	0.02%	579
2021 Q4	$1.33M	Buy	167,106 +11,247	+7%	+$103K	0.02%	605
2021 Q3	$1.74M	Buy	155,859 +4,543	+3%	+$58.8K	0.04%	354
2021 Q2	$2.21M	Buy	+151,316	New	+$2.34M	0.06%	282

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

NewEdge Advisors's LTRN Position: Q2 2026 in Review

NewEdge Advisors reduced its Lantern Pharma (LTRN) stake by 1.3% in Q2 2026, selling an estimated $1.03K and leaving 27,049 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2917.

NewEdge Advisors first reported a position in LTRN in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.21M in Q2 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

NewEdge Advisors held 27,049 shares of Lantern Pharma worth $113K as of Q2 2026.
NewEdge Advisors sold 350 Lantern Pharma shares in Q2 2026, an estimated $1.03K.
Lantern Pharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2917 holding.
NewEdge Advisors first reported a position in Lantern Pharma in Q2 2021 and has held it in 21 quarters since.
NewEdge Advisors's Lantern Pharma position peaked at $2.21M in Q2 2021.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.